Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum. (24th August 2022)

• Record Type: Journal Article
• Authors: Acierno, Sabrina; Angrisani, Francesca; Marino, Achille; Caporali, Roberto Felice; Cimaz, Rolando; Giani, Teresa
• Is Part Of: International journal of rheumatic diseases. Volume 25:Number 11(2022)
• Page Start: 1333
• Page End: 1338
• Publication Date: 2022-08-24
• Subjects: anakinra -- canakinumab -- chronic recurrent multifocal osteomyelitis -- IL‐1 -- pyoderma gangrenosum; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.14425
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a bone inflammatory disorder characterized by osteolytic, usually multiple, symmetric lesions. Diagnosis is one of exclusion, and no standardized therapies are available. Presumed deregulation of the interleukin (IL)‐1β axis, as observed in 2 monogenic autoinflammatory conditions such as Majeed syndrome (LPIN2 mutations) and deficiency of IL‐1 receptor antagonist (IL1RN mutations) with CRMO‐like bone involvement, suggests the blockade of IL‐1 as potentially useful also in this condition, even if scarce data are available. Case presentation: We report the case of a 13‐year‐old girl affected by a multidrug‐resistant and pyoderma gangrenosum‐complicated CRMO treated with canakinumab, a human monoclonal antibody targeting IL‐1β. Conclusion: In this young patient pyoderma gangrenosum and CRMO showed a rapid and satisfactory response to canakinumab, although over time a decreased efficacy in controlling bone disease was observed.